Overview
Roivant Sciences announced that its experimental drug mosliciguat achieved the primary endpoints of a Phase II trial involving 135 patients with pulmonary hypertension associated with interstitial lung disease (PH‑ILD). The trial demonstrated a 56.3% reduction in lung pressure and vascular resistance compared with placebo after 16 weeks. In addition, the secondary endpoint showed that participants receiving mosliciguat walked 35.2 meters farther in a six‑minute walk test than those on placebo at the same time point.
The company disclosed that its shares rose approximately 17% following the release of the data. Chief Investment Officer Mayukh Sukhatme highlighted the drug’s long half‑life, noting that it could be used both as a standalone therapy and in combination with other treatments, offering “real relief” and the possibility of reducing hospitalizations, exacerbations and deaths among patients with limited life expectancy.
Roivant also referenced its recent U.S. approval of Lisraya, a therapy for skin and muscle disease, underscoring its broader pipeline expansion efforts.
JPMorgan analyst Brian Cheng labeled Roivant a “top pick,” stating that the trial results suggest the market potential for mosliciguat in the PH‑ILD indication exceeds his earlier $1.5 billion risk‑adjusted peak‑sales estimate.